JG
CTXR icon

Joel Greenblatt’s Citius Pharmaceuticals CTXR Stock Holding History

Joel Greenblatt’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-879
Closed -$2.28M – 1224
2022
Q3 		$2.28M Buy
+879
New +$24.2K 0.07% 351

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Joel Greenblatt's CTXR Position: Q4 2022 in Review

Joel Greenblatt sold out of Citius Pharmaceuticals (CTXR) in Q4 2022, closing a stake of 879 shares — an estimated $2.28M sold.

Joel Greenblatt first reported a position in CTXR in Q3 2022 and held it in 1 quarter. The position peaked at $2.28M in Q3 2022. 54 funds tracked by Wall St. Rank hold CTXR as of Q4 2022.

  • Joel Greenblatt reported no remaining Citius Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Joel Greenblatt sold 879 Citius Pharmaceuticals shares in Q4 2022, an estimated $2.28M.
  • Joel Greenblatt first reported a position in Citius Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Joel Greenblatt's Citius Pharmaceuticals position peaked at $2.28M in Q3 2022.
  • 54 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2022.

Based on Gotham Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.